En metaanalyse der inkluderede ni studier viste, at fasteblodsukkeret hos patienter med type 1 - og type 2- diabetes var højere hos patienter behandlet med NovoMix 30 end hos patienter behandlet med bifasisk humant insulin 30.
A meta-analysis including nine trials in patients with type 1 and type 2 diabetes showed that fasting blood glucose was higher in patients treated with NovoMix 30, than in patients treated with biphasic human insulin 30.